Stocks · News reference
UBS has lowered its price target for Pacific Biosciences of California, Inc. while maintaining a Neutral rating on the stock.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pacific Biosciences of California, Inc. has entered into a sales agreement with Allen & Company to sell up to $100 million of its common stock through an at-the-market offering.
Filed: 2026-11-10 AccNo: 0001104659-26-125166 Size: 603 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
PacBio reported its third-quarter 2026 financial results, showing a 6% year-over-year revenue increase and a workforce reduction of approximately 8%.
Barclays maintained its Underweight rating on Pacific Biosciences and increased its price target from $1.25 to $2.00.
Piper Sandler maintained its Neutral rating on Pacific Biosciences and increased its price target from $2.00 to $3.00.